Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328755 | PMC |
| http://dx.doi.org/10.1016/j.xjon.2023.01.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fabrication of a three-dimensional scaffold-free trachea with horseshoe-shaped hyaline cartilage: comment.
Eur J Cardiothorac Surg
December 2024
Saveetha Medical College and Hospital Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.
The challenge and promise of disentangling neurodevelopmental conditions a commentary on Davis et al. (2024).
J Child Psychol Psychiatry
December 2024
Department of Psychology, University of Amsterdam, Amsterdam, The Netherlands.
This commentary evaluates the study by Davis et al. on the early behavioural manifestations of autism spectrum condition (ASC) and attention deficit hyperactivity disorder (ADHD) in preschool children. Davis et al.
View Article and Find Full Text PDFCommentary: Microsurgical Resection of a Left Eloquent Arteriovenous Malformation Presenting With Papilledema: 3-Dimensional Operative Video.
Oper Neurosurg (Hagerstown)
December 2024
Department of Neurological Surgery, Mayo Clinic, Phoenix, Arizona, USA.
New Fetal Sonographic Marker to Rule Out Total Anomalous Pulmonary Venous Return: Color Doppler Drainage From Pulmonary Vein to Atrium to Ventricle (CDDVAV).
Echocardiography
December 2024
Division of Pediatric Cardiology, Department of Pediatrics, Mattel Children's Hospital, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Article Synopsis
- Total anomalous pulmonary venous return (TAPVR) can cause severe issues shortly after birth, making early detection crucial for better outcomes.
- Despite being a serious congenital heart condition, TAPVR is often not diagnosed before birth, even though there are known ultrasound markers.
- This commentary introduces a new color Doppler fetal sonographic marker that could help identify TAPVR prenatally, potentially preventing life-threatening complications.
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.
JAMA Cardiol
January 2025
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
Article Synopsis
- The study investigates the safety and efficacy of finerenone in treating heart failure, focusing on differences between men and women.
- Conducted as part of the FINEARTS-HF trial, it included over 6000 participants aged 40 and older across multiple countries.
- Results show that finerenone significantly reduces the risk of combined cardiovascular death and heart failure events in both sexes, with women experiencing slightly better outcomes on average.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!